Stay updated on GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Sign up to get notified when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.

Latest updates to the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page
- Check4 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check11 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 19, 2025.SummaryDifference1.0%
- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check54 days agoChange DetectedThe page has added a Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/Refractory AML (AGORA-1) with a date of 2025-02-19, while the previous entry for the same study dated 2023-11-13 has been removed.SummaryDifference7%
- Check68 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check76 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check90 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
Stay in the know with updates to GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GO-Gilteritinib Combo in FLT3-ITD AML Clinical Trial page.